Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

IS SENTINEL LYMPH NODE BIOPSY WITH RADIOTHERAPY ALONE WITHOUT AXILLARY LYMPH NODE DISSECTION SAFE FOLLOWING NEOADJUVANT CHEMOTHERAPY IN INITIALLY CLINICALLY AXILLA POSITIVE PATIENTS: NEOSENTITURK-TRIAL/MF-18-03

NCT04250129 is registered in ClinicalTrials.gov with Federation of Breast Diseases Societies as lead sponsor.

NCT NCT04250129
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04250129 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
IS SENTINEL LYMPH NODE BIOPSY WITH RADIOTHERAPY ALONE WITHOUT AXILLARY LYMPH NODE DISSECTION SAFE FOLLOWING NEOADJUVANT CHEMOTHERAPY IN INITIALLY CLINICALLY AXILLA POSITIVE PATIENTS: NEOSENTITURK-TRIAL/MF-18-03
Lead sponsor
Federation of Breast Diseases Societies
Phase
Observational
Overall status
Unknown status
Start date
January 31, 2018
Completion date
January 31, 2023
Enrollment
500 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

sentinel lymph node